The FDA's acceptance of the supplemental application for SPRAVATO signifies a potential label expansion, which could strengthen Janssen's position in the competitive landscape of depression therapies. This development warrants close monitoring as it may influence market dynamics and sales forecasts. Regulatory context from FDA (FDA AP — SPRAVATO (SUPPL)) supports the near-term read. Assessment grounded in 22 ranked evidence items (4 high-relevance).